Supporters and Exhibitors

The MIBC Congress would like to thank the supporters. It is with the support of the industry that we can continue in our mission to promote research and education and to disseminate new knowledge.

Gold Supporters

Silver Supporters

Bronze Supporters

Supporters

Exhibitors

Endotherapeutics is an Australian distributor of specialist medical devices. We are committed to successfully registering new medical products in Australia and New Zealand, marketing the portfolio with a team of highly trained product specialists, and driving the adoption of minimally or less invasive innovative medical technologies. Endotherapeutics prides itself on the high level of customer service and clinical support provided to the healthcare specialist.

For over 100 years, C. R. Bard, Inc. has been Advancing the Delivery of Healthcare by creating innovative products and services that meet the needs of healthcare providers and patients. Today, Bard is a leader in products that focus on Disease State Management in three key areas: Vascular, Urology, and Oncology. To complement these areas, Bard has a complete line of advanced Surgical Specialty Products and Services.
Focused on our core values of Quality, Integrity, Service and Innovation, Bard Medical will improve the quality of patient healthcare with essential, cost efficient medical devices that provide effective clinical outcomes. This makes us a provider of choice for clinicians in the venous access, urology and women’s health disease states.

Bio-Strategy is an established locally-owned, ISO 9001:2015 accredited distributor, delivering technology to the Scientific Community throughout Australasia., and the exclusive distributor of NanoString Technologies Inc. throughout Australia and New Zealand.
The Prosigna™ Breast Cancer Prognostic Gene Signature Assay is the first in vitro diagnostic from NanoString Technologies Inc. Prosigna was developed based on the PAM50 gene signature, which measures expression of 50 genes. Prosigna results provide a patient’s risk of distant recurrence and classify tumors into 1 of 4 intrinsic subtypes to guide clinical decisions. Prosigna and the nCounter Analysis System are TGA registered in Australia, have FDA 510k clearance in the USA and CE-mark designation in Europe.
For more information on Prosigna visit: www.prosigna.com

Regional Health Care Group (RHCG) is proud to exhibit at the Melbourne International Breast Conference 2018…
• Paxman® Scalp Cooling System; the Australian & Global market leader for helping cancer patients avoid Chemotherapy induced hair-loss.
• ImpediMed® Non-invasive fluid & tissue analysis technology with bilateral lymphedema monitoring capability
• iCAD XOFT® System for intraoperative radiotherapy (IORT) during Breast Cancer surgery, Gynae & Skin Cancers.
RHCG is highly regarded in all clinical settings across Australia & NZ; providing specialist medical consumables supplies & support; delivering quality products, excellent service & cost-savings.
For further information, please visit our website at www.rhcg.com.au or call 1300 659281

Sonic Healthcare is Australia’s largest provider of pathology testing and the third largest in the world, with operations in eight countries.
Sonic Genetics is a specialist genetics service that brings together Sonic Healthcare’s national and international expertise to provide a comprehensive range of high quality, accredited genetic tests to doctors, patients and families across Australia.
Our MIBC 2018 presentation focuses on the TGA registered Prosigna® Breast Cancer Prognostic Gene Signature Assay which provides a patient’s risk of distant recurrence and classifies tumours into one of four intrinsic subtypes to guide clinical decisions. Prosigna® is based on the PAM50 gene signature that measures the expression of 50 genes.
Prosigna® is performed in an accredited Australian laboratory and provides clinicians with the most comprehensive and actionable results at a cost-effective price. For further information, please come to our booth, visit www.sonicgenetics.com.au/tests/prosigna or call us on 1800 010 447.

Volpara will showcase its suite of quantitative breast imaging tools, which allow for personalised measurements of volumetric breast density, patient dose, breast compression and other factors designed to help maintain accuracy and consistent quality in mammography. With its VolparaDensity and cloud-based VolparaEnterprise software, Volpara is the market leader in both breast density analysis and quality and performance analytics for breast imaging centres.
Volpara’s software is the most clinically validated of its kind in the world, featured in over 240 medical publications, and is supported by numerous patents, trademarks and regulatory clearances.
For further information, please visit our website at www.volparasolutions.com

Integra, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopaedic extremity surgery, neurosurgery, and reconstructive and general surgery. Integra is a leader in neurosurgery, offering a broad portfolio of implants, devices, instruments and systems used in neurosurgery, neuromonitoring, neurotrauma, and related critical care. Other Integra products include peripheral nerve protection and repair, and wound repair.
For further information, please visit our website at www.integralife.com

AstraZeneca is the ninth largest pharmaceutical company operating in Australia. It is one of the country’s largest manufacturers of medicines and is a key exporter to 20 international markets.
AstraZeneca produces medicines in a range of therapeutic areas including Oncology, Cardiovascular & Metabolic Diseases and Respiratory.
AstraZeneca contributes significantly to clinical trials in Australia with over 55 concurrent trials. AstraZeneca’s innovative medicines are used by millions of patients worldwide. For more information visit www.astrazeneca.com.au.

Our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide. At MSD, helping people fight cancer is our passion and supporting accessibility to our cancer medicines is our commitment. Our focus is on pursuing research in immuno-oncology and we are accelerating every step in the journey – from lab to clinic – to potentially bring new hope to people with cancer.
For more information visit www.msd.com.

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information visit www.amgen.com.

Eisai (pronounced ‘ā-zī’) is derived from the Japanese word for ‘health product’ and, here at Eisai, we discover, develop and market innovative, high quality medicines throughout the world.
We define our corporate mission as “giving first thought to patients and their families, and to increasing the benefits health care provides,” which we call human health care (hhc). With operations in the U.S., Asia, Europe and its home market of Japan, Eisai employs more than 11,000 people worldwide.
Eisai focuses its efforts in several therapeutic areas and in Australia, Neurology and Oncology are our primary specialty areas.
For more information visit www.eisai.com.au.

The Carl Zeiss Group is a leading group of companies operating worldwide in the optical and opto-electronic industries. Headquartered in Oberkochen, Germany, Carl Zeiss is represented in more than 30 countries, with around 30 production sites and 50 sales and service sites around the world.
ZEISS is a leader in ophthalmic and surgical microscopes from dental to the latest technology neurosurgical systems. Since 1997, ZEISS has also been a leader in Intraoperative Radiotherapy (IORT) with the introduction of INTRABEAM®. Radical surgical methods in the treatment of breast cancer are being replaced by less-invasive, breast-conserving therapy and this trend is appearing in radiotherapy where oncologists are moving from the largely standardised treatment plan to risk-adapted and targeted individualised therapy.
Visit the ZEISS stand at MIBC 2018 to experience the INTRABEAM® www.zeiss.com.au.

At Novartis, our mission is to discover new ways to improve and extend people’s lives. We use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
As leader in oncology, Novartis offers a portfolio of more than 20 approved therapies and approximately 30 compounds in development.
We are passionate about what we do and the impact we have on patients and societies.
We are Novartis, and we are reimagining medicine.
For more information visit www.novartis.com.

Myriad is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.
EndoPredict is a 2nd generation breast cancer recurrence test that combines the prognostic power of a 12-Gene Molecular Score with tumor size and lymph node status. EndoPredict provides a comprehensive assessment of the 10-year risk of distant recurrence for women with ER+, HER2- early-stage breast cancer when treated with 5-years of endocrine therapy.
For more information visit www.myriad.com.

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve
people’s lives.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in-vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them antibiotics, antimalarials and cancer medicines. Roche has been recognised as the leading healthcare company in the Dow Jones Sustainability Indices since 2009.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. Roche invests around 10 billion US Dollars each year in research and development worldwide, including over AUD 37 million in pharmaceuticals in Australia. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
Roche’s pharmaceutical division in Australia employs over 350 people who are dedicated to the clinical development, registration, sales, marketing and distribution of innovative pharmaceutical medicines. Australian patients have access to around 40 Roche medicines, and the company is the leading provider of cancer medicines in Australia by sales.
For more information visit www.roche-australia.com.

Aurora BioScience is a leading medical device distribution company. Our network extends across metropolitan and regional areas throughout Australia, New Zealand and the Pacific Islands.
Our growing product range includes some of the world’s most innovative medical products and solutions in cancer care and other specialty areas.
Some of the products on our stand include Trunode, our single-use wireless Gamma Probe with industry leading sensitivity, the range of Faxitron X-Ray Cabinets and Surgical Specimen systems as well as the original scalp cooling system, the DigniCAP for hair preservation during chemotherapy.
We look forward to seeing you at the conference.
For more information visit www.aurorabioscience.com.au.

GenesisCare is a global leader in radiation therapy, with treatment centres across Australia, the United Kingdom, and Spain providing the highest levels of patient-focused care across a network of conveniently located, purpose-built cancer centres.
From the moment a patient is referred, they have prompt access to diagnostic procedures and tests, as well as treatments including advanced radiation therapy and chemotherapy in selected locations.
At the heart of each centre is GenesisCare’s approach to radiotherapy – one that leads the way in providing patients with the most precise treatment available resulting in fewer side-effects and improved outcomes for patients.
For more information visit www.cancer.com.au.

Radiation oncology is our speciality. We supply CyberKnife, Radixact, and TomoTherapy delivery systems from Accuray, MacroMedics positioning and immobilisation devices, RaySearch TPS, IsoAid seed-kits for interstitial brachytherapy & radioactive seed localisation, Sensus superficial X-Ray, and PXI irradiators used in cancer research.
We also have the widest range of leading medical physics quality assurance and test tools from Sun Nuclear, Gammex and CIRS.
With our experienced Radiation Therapists, Medical Physicists, Medical IT Specialists and Service Engineers, we provide the best customer service solution: from equipment selection, through to ongoing product training, maintenance and support.
For more information visit www.alphaxrt.com.

Medical Specialties Australasia (MSA) was founded in 1982 on the introduction of next generation technology and has pioneered the establishment of many new medical and surgical technologies in the Australasia region including first Vascular Access Port, Implantable Pump, PICC Line, AAA Stent Graft and Insulin Pump. Our customers receive comprehensive support through our highly trained field representatives, clinical educators, technical services specialists and customer service team.
For more information visit www.msa.com.au/.

At LifeHealthcare we bring Australian and New Zealand healthcare professionals innovative medical devices by partnering with world class companies who share our vision for innovation and making a real difference to people’s lives. Together with our partners all over the world, our people work closely with healthcare professionals to ensure the highest standards of patient care.
For more information visit www.lifehealthcare.com.au/.

Icon has a long history of delivering exceptional cancer care for the Australian community. Icon Cancer Centres are a combination of day oncology hospitals, radiation oncology centres and comprehensive facilities that bring both day oncology and radiation disciplines together under one roof. Our 26 centres across metropolitan and regional Australia are supported by the latest technology and a network of over 150 highly experienced oncologists. With pharmacy and chemotherapy compounding functions operating as part of Icon, our team work as one to ensure a seamless and safe approach to care every step of the way.
With 30 years of experience in private cancer care, we understand our patients. We walk them through their cancer diagnosis and treatment with knowledge and compassion.
For more information visit www.iconcancercentre.com.au.

Harnessing data and analytics across hardware, software and biotech, GE Healthcare is the $19 billion healthcare business of GE (NYSE: GE). As a leading provider of medical imaging equipment, with a track record of more than 100 years in the industry and more than 50,000 employees across 100 countries, we transform healthcare by delivering better outcomes for providers and patients. Follow us on Facebook, LinkedIn, Twitter and The Pulse for latest news.
For more information visit www.gehealthcare.com.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products. The Company’s core business units focus on diagnostics, breast health, GYN surgical, and skeletal health. With a unified suite of technologies and a robust research and development program, Hologic is dedicated to The Science of Sure.
For more information visit www.hologic.com.

Genomic Health, Inc. is the world’s leading provider of genomic-based diagnostic tests that help optimize cancer care, including addressing the overtreatment of the disease. With its Oncotype IQ® Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company’s flagship line of Oncotype DX® gene expression tests that have been used to guide treatment decisions for more than 900,000 cancer patients worldwide. The company is based in Redwood City, California, with international headquarters in Geneva, Switzerland.
For more information visit www.GenomicHealth.com .

GRC Surgical specialises in high quality devices for women’s health with a focus on technologies that can optimise outcomes in patients with breast cancer.
GRC’s philosophy is sophisticated technology made simple, advanced detection systems designed for ease of use and accuracy.
For more information visit www.grcsurgical.com.

Smith & Nephew is a global medical technology company with a focus on repairing and healing the human body in three high-growth sectors: Orthopaedics, Endoscopy, Wound Management and ENT.
The company creates innovative products, whose performance has earned the trust of clinicians around the world. We are very proud that every day our products help improve people’s lives.
The Wound Management portfolio features:
• Products that speed up the healing process in difficult-to-heal wounds
• Dressings and products for acute and chronic wounds, including diabetic wounds and burns
For more information visit www.smith-nephew.com/australia.

MENTOR
A Global Leader in Aesthetic Medicine.
Founded in 1969, Mentor Worldwide LLC is a leading global manufacturer of high quality breast implants.
Headquartered in Santa Barbara, California. Mentor has manufacturing and research operations in the United States and the Netherlands.
Mentor has over 30 years of experience in the manufacture of breast implants and tissue expanders. Our experience and expertise results in quality products you can rely on.
Mentor and our 1,200 worldwide employees strive to provide high-quality products and services to healthcare professionals and patients.
In January 2009, Mentors was acquired by Johnson & Johnson. Together we aim to enhance and restore self-esteem and quality of life. Simply said, our mission is to Make Life More Beautiful.
For more information visit www.jjmc.ca/our-products/mentor.

Defries Industries is an Australian owned company that designs, develops and supplies innovative quality finished medical and surgical products throughout Australia and New Zealand. As a world class manufacturer, we are committed to suppling high quality products that excel in design, ease of use, safety and price.
Operating for over 37 years, we supply a wide range of single use products to our customers. Our specialties include custom procedure packs, surgical equipment and drapes, clinical protective apparel, theatre consumables, disposable bowls, wound care, sterilised consumables, surgical dressings, tapes and bandages, and custom printed labels.
For more information visit www.defries.com.au.

Pfizer Oncology works collaboratively with academic institutions, individual researchers, cooperative research groups, governments and licensing partners to further its extensive research and development program.
We are committed to partnerships with professional and patient organisations that deliver benefits to patients including disease management tools, awareness of clinical trial options and access to new medicines.
Working together, we strive to transform treatment by targeting the right drug for the right patient at theright time.
For more information about Pfizer Oncology, please visit www.pfizer.com.au.

Surgeons Choice continues to exclusively provide sales, support and service for the Navigator range of Sentinel Node Probe systems in Australia.
We are showcasing a next generation innovative liquid nitrogen Cryoablation System providing the coldest, fastest most stable Cryoablation Technology in the market, for treatment of benign and some malignant breast tumors.
For more information visit www.surgeonschoice.net.au.

Breast Cancer Network Australia (BCNA) is the peak national organisation for Australians affected by breast cancer with more than 120,000 members.
Representing the people behind the statistics, BCNA works to ensure the voices of everyday Australians affected by breast cancer are heard and that they receive the very best support, information, treatment and care appropriate to their individual needs.
For more information visit www.bcna.org.au.

Matrix Surgical is a supplier, manufacturer and importer of innovative and affordable surgical equipment, with a focus on laparoscopic instruments and accessories.
Matrix Surgical was cofounded in 1995 and takes pride in offering ‘Quality Surgical Solutions for the Best Patient Outcome’.
Today Matrix Surgical has a direct sales force in every state of Australia and licenced distributors in New Zealand.
We’ve made it our mission to source or manufacture products that make life in the operating theatre easier and more efficient.
As well as finding and developing new products we also adapt our existing products and combinations to suit your needs.
For more information visit www.matrixsurgical.com.au.

Surgical Supplies Australia are an Australian owned distributor of medical devices and associated products across plastic, cosmetic and reconstructive surgery. SSA’s strategy is to bring to the Australian market best of breed products that are innovative and deliver a clear point of difference.
As a boutique style distribution company we focus heavily on service and service delivery to our customers. This provides our customers with the confidence to know that when dealing with SSA they can rely on an un-paralled level of service and product delivery.
We have a team of highly trained sales professionals servicing all states of Australia with year of experience in our fields looking forward to delivering your product needs.
For more information visit www.surgsa.com.au.

Medilink has been providing solutions to medical imaging departments since 1991. We offer a range of diagnostic display systems, CD/DVD publishers and X-ray cabinets.
Medilink represents Kubtec® in Australia. Kubtec® produce diagnostic imaging systems that enable medical professionals to provide the best quality of care for patients.
Their systems include 3-D breast specimen tomosynthesis for breast cancer treatment and Advanced 2-D digital X-ray imaging for pathology, biopsy and the operating theatre with the aim of redefining medical imaging and healthcare standards for the 21st century.
For more information visit www.medilinkaustralia.com.

Specialised Therapeutics Australia is a privately-held international pharmaceutical company providing new specialist medicines to patients in Australia, New Zealand and across South-East Asia. Dually headquartered in Melbourne, Australia and Singapore, STA and its affiliate company Specialised Therapeutics Asia Pte Ltd collaborates with leading global pharmaceutical, biotech and diagnostic companies to bring innovative specialist therapies and technologies to patients in key regions. The current oncology portfolio includes ABRAXANE (nanoparticle albumin-bound paclitaxel), NERLYNX (neratinib) as well as the Oncotype DX breast cancer assay. In addition, ST holds a robust portfolio of haematology, supportive care, neurology and ophthalmology medicines.
For more information visit www.stbiopharma.com.

Melbourne Pathology is the premier provider of pathology services in Victoria, with over 90 years of commitment to diagnostic excellence and customer service. They form a part of Sonic Healthcare, an Australian owned company that is one of the world’s largest diagnostic medical companies.
Melbourne Pathology’s highly experienced team of pathologists are leaders in their field with specialist knowledge and expertise in clinical pathology, cytopathology and anatomical pathology, including breast pathology. They provide current, informed and practical advice to assist with interpretation of results and are available for consultation.
Melbourne Pathology has state-of-the-art, 24-hour laboratories located in Collingwood, Richmond, Box Hill and Mulgrave, and additional laboratories in Geelong, Mornington, Footscray, Moe, Bendigo and Ballarat. These laboratories support almost 300 collection centres throughout Melbourne and Victoria.
Through Sonic Genetics (part of Sonic Healthcare), the TGA registered Prosigna® Breast Cancer Prognostic Gene Signature Assay and Contextual Genomics Find It® Cancer Hotspot Panel provides clinicians with the most comprehensive and actionable results at a cost-effective price.
Melbourne Pathology offers experience, knowledge, dedicated pathologists and a quality pathology service.
For more information visit www.mps.com.au.

For over 25 years, Device Technologies has been pioneering possibility in the Australasian healthcare landscape – seeking out and bringing to market, some of the world’s most advanced healthcare products. From high-quality consumables to advanced theatre equipment and robotics, Device Technologies is Australasia’s largest independent provider of medical solutions and technologies. Partnering with the world’s most innovative medical companies, we offer a comprehensive range of supplies with client care at the core of our values. Our dedicated team of over 650 highly skilled healthcare specialists and support staff, is committed to providing superior outcomes for healthcare professionals and their patients across the entire healthcare community.
For more information visit www.device.com.au.

Spiran is a boutique brand that encompasses highly innovative products which are collectively recognized by Australia’s leading Plastic Surgeons as the aspirational brands to associate with. We have a truly patient and client centric approach; our industry specific and highly experienced team are truly dedicated to inspiring Australian surgeons, support staff and their patients to be the best they can be in life, surgery and business, while achieving their goals through utilizing superior products and highly innovative technologies.
We believe in innovation, inspiration and a truly amazing total customer experience; whether you are a patient, a surgeon or a clinic we aspire to ensure plastic surgeons and their patients have the very best experience, each step of the way, to be the best they can be and feel inspired everyday!
For more information visit www.spiran.care.

Lilly Oncology is dedicated to advancing treatment and addressing the unmet needs of people living with cancer, and for more than five decades, we have been delivering innovative solutions. Currently, we are committed to creating a broad portfolio, with research focused in three areas:
• Tumour cell signalling,
• Microenvironment, and
• Immuno-oncology
We are exploring different combinations and sequencing of therapy so we can help advance treatment for more people.
Our hope is to optimize cancer patient outcomes and find meaningful and practical ways to support patients, caregivers, and the cancer care team.
For more information visit www.lilly.com.

Aspen Australia is an affiliate of the International Aspen Group, it is the largest non-generic supplier of medicines by volume in Australia.
Aspen manufactures, markets and distributes pharmaceutical products in most therapeutic categories. The Aspen range includes Prescription Pharmaceutical brands, Speciality pharmaceutical products, OTC healthcare, and Nutritional products.
For more information visit www.aspenpharma.com.au.

ANSTO leverages great science to deliver big outcomes. We partner with scientists and engineers to provide real-world benefits in the areas of human health, solutions for industry and the environment.
Thousands of scientists from industry and academia benefit from gaining access to ANSTO’s research infrastructure every year.
For example, Sydney University is using the Imaging and Medical Beamline at ANSTO’s Australian Synchrotron as part of ongoing research into an innovative imaging technique – in-line phase-contrast computed tomography – to improve the detection and diagnosis of breast cancer. The new technique has prospective advantages over conventional X-rays in that it provides better image quality with less radiation dose.
For more information visit www.ansto.gov.au.

EBOS Healthcare ANZ in partnership with Endomag UK promote the clinical and economic benefits of market leading magnetic technology for the staging of breast cancer and lesion localisation. Sentimag® and Sienna® (magnetic tracer) were initially developed for staging breast cancer, used as an alternative to radioisotopes and blue dye for sentinel lymph node biopsy.
Magseed® is designed to guide surgeons using Sentimag® during a breast lumpectomy. Magseed® was developed to simplify treatment, improve patient experience and support better outcomes. Since its initial launch, Magseed® technology has been further developed with potential application for marking nodes in neo adjuvant chemotherapy patients.
For more information visit www.eboshealthcare.co.nz.